Fresenius Kabi AG Announces Availability of Acetylcysteine Solution, USP, 20%
Published: Oct 01, 2012
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi USA, LLC today announced the launch of Acetylcysteine Solution, USP, 20% 30 mL vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote). For inhalation, it is used as adjuvant therapy for patients with certain lung diseases including chronic and acute bronchopulmonary disease. Inhalation therapy reduces the viscosity of mucus, thinning mucus secretions. When administered orally, it is used to prevent or lessen hepatic injury following acetaminophen overdose.